59 results on '"Giaj-Levra, N."'
Search Results
2. PO-1134 Repeated SRS with linac-based monoisocentric technique in recurrent intracranial metastases.
3. PO-1486 Feasibility and tolerability of MR-guided adaptive RT on prostatic bed:mono-institutional experience.
4. PO-1452 Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia.
5. PO-1256: Feasibility and initial results of Linac-based Stereotactic Body Radiotherapy in spinal metastases.
6. PO-1439 Clinical results of SBRT for spinal metastases using dedicated contouring/planning system.
7. PO-1841: Efficacy of a new dedicated immobilization device for treatment of Central Nervous disease.
8. EP-1347 "Risk adapative" dose prescription in central NSCLC lesions in early stage NSCLC and lung metastases.
9. EP-1225 Stereotactic Radiotherapy for Spine metastases using Brainlab® Elements Spine: preliminary results.
10. EP-1206: FDG-PET/CT predictive parameters of early response after SABR for lung oligometastases.
11. EP-1104: SABR for brain metastases with VMAT and FFF: feasibility and early clinical results.
12. EP-1335: Prostate cancer hypofractionation: impact of prostate gland dimension in genitourinary toxicity.
13. EP-1153: Hypofractionated radiotherapy and simultaneous boost in breast cancer: preliminary result in elderly.
14. EP-1347: Hypofractionated whole brain irradiation with hippocampal sparing and SIB for metastases: a dosimetric VMAT study.
15. PO-1601 Stereotactic body radiotherapy (SBRT) with or without dose boost in spinal oligometastatic patients.
16. PO-1000: Multicentric restrospective analysis of safety of SBRT to centrally located lesion of the lung.
17. PO-1530 Prostate SBRT on 1.5T MR-linac or linac-based VMAT: a comparison study from a prospective trial.
18. PO-1540 1.5T MR-guided daily-adapted SBRT on lymphnode oligometastases from prostate cancer.
19. PD-0071 SBRT for spine oligometastases: a multicenter retrospective study on behalf of AIRO.
20. PO-1773 Feasibility of a novel harmonization method for NSCLC multi-centric radiomic studies.
21. PO-1463 SBRT for over 80years oligometastatic patients: report of feasibility and clinical outcomes.
22. PD-0575 Toxicity and QoL report of 1.5T MR-guided SBRT for prostate cancer in the first 100 patients.
23. PD-0250 Therapeutic use of Linac-based SRS in malignant spasticity: early results from a prospective trial.
24. PD-0086 PSMA-PET guided stereotactic body radiotherapy for bone oligorecurrent prostate cancer.
25. EP-1151: Hypofractionated Radiotherapy in breast cancer treatment: A comparison between 3-DCRT and IMRT.
26. EP-1441: IMRT in elderly woman with breast cancer: are comorbidities related to toxicity?
27. PO-1512 Daily adaptive MR-guided SBRT for oligometastatic lymph-nodes:feasibility and preliminary experience.
28. PO-1388 1.5 T MR-guided SBRT for oligorecurrent prostate cancer: preliminary report of feasibility and PROMs.
29. PO-1353 Postoperative hypofractionated RT for prostate adenocarcinoma: results from a large series.
30. PO-1153 Preliminary mono-institutional report of stereotactic body radiotherapy for lung oligometastases.
31. EP-1222: Impact of 18F-Choline PET in the decision making strategy of treatment volumes in definitive prostate radiotherapy.
32. PO-1407 Postoperative hypofractionated RT: toxicity and efficacy in a series of 304 prostate adenocarcinoma.
33. PO-1353 SBRT for gynecological oligometastases: mono-institutional report of toxicity and clinical outcomes.
34. PO-1188 Stereotactic body RT (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer.
35. PD-0574 1.5T MR-guided RT versus linac-based VMAT SBRT in localized prostate cancer: a toxicity comparison.
36. PO-1193: 18F-CHOLINE PET/68Ga-PSMA PET SBRT in oligorecurrent prostate cancer: comparative analysis.
37. PO-1062: Stereotactic body radiotherapy can delay polymetastatic conversion in liver oligometastatic patients.
38. PD-0175: TTIRS trial:a retrospective analysis of the association between TT or IT and RS for BM from NSCLC.
39. PD-0463: Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels.
40. PO-1499 1.5T MR-guided daily adaptive radiotherapy: preliminary clinical report of the first 2000 fractions.
41. PO-1376 Preliminary mono-institutional report of prostate/prostate bed SBRT re-irradiation.
42. EP-1558 Updated results of a Phase II study on 5 fractions FFF SBRT for low and intermediate prostate cancer.
43. EP-1209 First clinical results using HyperArcTM and Linac-based VMAT radiosurgery in brain metastases.
44. PO-1163: 68Ga-PSMA PET-Guided metastases directed stereotactic body radiotherapy in prostatic cancer patients.
45. PO-1162: Post hifu salvage radiotherapy in locally relapsed prostate carcinoma: a mono-institutional analysis.
46. PO-1027: Disease natural history of lung oligometastatic colo-rectal cancer patients treated with SBRT.
47. PV-0047 IMRT versus VMAT for elderly patients with breast cancer: comparison of acute and late toxicities.
48. EP-1103: Are hippocampi considered organs at risks during stereotactic radiotherapy for brain metastases?
49. PO-0723: Phase II study with FFF linac-based SBRT in 5 fractions for localized prostate cancer.
50. EP-1316: Moderate Hypofractionation RT in postprostatectomy setting:report on feasibility and acute toxicity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.